CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
- PMID: 25642417
- PMCID: PMC4295550
- DOI: 10.3389/fonc.2014.00385
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Abstract
Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.
Keywords: CLTA-4; PD-1; immunotherapy; ipilimumab; nivolumab.
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18. Expert Opin Biol Ther. 2017. PMID: 28064556 Review.
-
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Eur Urol. 2015. PMID: 25824720 Review.
-
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.Pharmacol Res. 2022 Jan;175:105997. doi: 10.1016/j.phrs.2021.105997. Epub 2021 Nov 24. Pharmacol Res. 2022. PMID: 34826600 Review.
-
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.N Engl J Med. 2018 Nov 29;379(22):2185. doi: 10.1056/NEJMx180040. Epub 2018 Nov 9. N Engl J Med. 2018. PMID: 31442371 No abstract available.
Cited by
-
Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study.Vaccines (Basel). 2024 Aug 23;12(9):955. doi: 10.3390/vaccines12090955. Vaccines (Basel). 2024. PMID: 39339987 Free PMC article.
-
Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current Knowledge.Int J Mol Sci. 2024 Aug 31;25(17):9506. doi: 10.3390/ijms25179506. Int J Mol Sci. 2024. PMID: 39273452 Free PMC article. Review.
-
A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy.Cell Death Dis. 2024 Jun 1;15(6):386. doi: 10.1038/s41419-024-06776-6. Cell Death Dis. 2024. PMID: 38824143 Free PMC article.
-
Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.J Immunol. 2024 Mar 1;212(5):917-927. doi: 10.4049/jimmunol.2300618. J Immunol. 2024. PMID: 38214607 Free PMC article.
-
Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.Front Immunol. 2023 Oct 23;14:1280741. doi: 10.3389/fimmu.2023.1280741. eCollection 2023. Front Immunol. 2023. PMID: 37936703 Free PMC article. Review.
References
-
- Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 13:5. Available frpm: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559193/ - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources